Potential Diagnostic Value of Red Blood Cells α-Synuclein Heteroaggregates in Alzheimer’s Disease

[1]  W. M. van der Flier,et al.  Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes , 2018, Annals of neurology.

[2]  O. Sporns,et al.  Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers , 2018, Alzheimer's & Dementia.

[3]  M. Chupin,et al.  Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers , 2018, Alzheimer's & Dementia.

[4]  M. Trincavelli,et al.  α-Synuclein Aggregates with β-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects , 2017, Molecular Neurobiology.

[5]  M. Trincavelli,et al.  α-Synuclein Heterocomplexes with β-Amyloid Are Increased in Red Blood Cells of Parkinson’s Disease Patients and Correlate with Disease Severity , 2018, Front. Mol. Neurosci..

[6]  N. Buckley,et al.  Convergent molecular defects underpin diverse neurodegenerative diseases , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[7]  M. Trincavelli,et al.  α-Synuclein Aggregated with Tau and β-Amyloid in Human Platelets from Healthy Subjects: Correlation with Physical Exercise , 2018, Front. Aging Neurosci..

[8]  D. Mastroeni,et al.  Peripheral complement interactions with amyloid β peptide: Erythrocyte clearance mechanisms , 2017, Alzheimer's & Dementia.

[9]  C. Masters,et al.  A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain , 2017, Nature Reviews Neurology.

[10]  U. Bonuccelli,et al.  A single center study: Aβ42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting , 2017, Neurological Sciences.

[11]  M. Trincavelli,et al.  Influence of physical exercise on β-amyloid, α-synuclein and tau accumulation: an in vitro model of oxidative stress in human red blood cells. , 2017, Archives italiennes de biologie.

[12]  E. Masliah,et al.  Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson’s disease , 2017, Scientific Reports.

[13]  C. Martini,et al.  Potential biomarkers and novel pharmacological targets in protein aggregation‐related neurodegenerative diseases , 2017, Biochemical pharmacology.

[14]  D. Krainc,et al.  α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies , 2017, Nature Medicine.

[15]  J. Gramsbergen,et al.  Cerebrospinal fluid biomarkers for Parkinson's disease – a systematic review , 2017, Acta neurologica Scandinavica.

[16]  Philip S. Insel,et al.  Plasma tau in Alzheimer disease , 2016, Neurology.

[17]  Eric E. Smith,et al.  Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development , 2016, Alzheimer's & dementia.

[18]  N. Toschi,et al.  Biomarker-guided classification scheme of neurodegenerative diseases , 2016, Journal of sport and health science.

[19]  K. Blennow,et al.  Alzheimer's disease , 2016, The Lancet.

[20]  G. Kovacs.  Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine , 2016, International journal of molecular sciences.

[21]  U. Sengupta,et al.  Pathological Interface Between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies , 2015, Biological Psychiatry.

[22]  G. Giannaccini,et al.  Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge. , 2015, Central nervous system agents in medicinal chemistry.

[23]  J. Lan,et al.  The peripheral blood of Aβ binding RBC as a biomarker for diagnosis of Alzheimer's disease. , 2015, Age and ageing.

[24]  Kui Ye,et al.  Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders , 2015, International Psychogeriatrics.

[25]  P. Deyn,et al.  Increased CSF α-synuclein levels in Alzheimer's disease: Correlation with tau levels , 2014, Alzheimer's & Dementia.

[26]  Ming-Jang Chiu,et al.  Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease. , 2014, ACS chemical neuroscience.

[27]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[28]  K. Blennow,et al.  Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[29]  E. Novellino,et al.  Apoptosis Therapy in Cancer: The First Single-molecule Co-activating p53 and the Translocator Protein in Glioblastoma , 2014, Scientific Reports.

[30]  M. Trincavelli,et al.  A Rapid and Efficient Immunoenzymatic Assay to Detect Receptor Protein Interactions: G Protein-Coupled Receptors , 2014, International journal of molecular sciences.

[31]  Philip S. Insel,et al.  Effects of Baseline CSF α-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer’s Disease , 2013, PloS one.

[32]  Ming-Jang Chiu,et al.  Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease. , 2013, ACS chemical neuroscience.

[33]  Nick C Fox,et al.  Molecular nexopathies: a new paradigm of neurodegenerative disease , 2013, Trends in Neurosciences.

[34]  C. Rowe,et al.  Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing , 2013, Molecular Psychiatry.

[35]  Christine Haberler,et al.  Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series , 2013, Acta Neuropathologica.

[36]  P. Calabresi,et al.  Cerebrospinal fluid biomarkers in Parkinson disease , 2013, Nature Reviews Neurology.

[37]  D. Wishart,et al.  Translational biomarker discovery in clinical metabolomics: an introductory tutorial , 2012, Metabolomics.

[38]  P. Yip,et al.  New assay for old markers-plasma beta amyloid of mild cognitive impairment and Alzheimer's disease. , 2012, Current Alzheimer research.

[39]  H. Arai,et al.  Amyloid β Levels in Human Red Blood Cells , 2012, PloS one.

[40]  Pedro Pesini,et al.  Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD , 2012, International journal of Alzheimer's disease.

[41]  D. Dickson.  Parkinson's disease and parkinsonism: neuropathology. , 2012, Cold Spring Harbor perspectives in medicine.

[42]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[43]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[44]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[45]  Frank Baumann,et al.  Peripherally Applied Aβ-Containing Inoculates Induce Cerebral β-Amyloidosis , 2010, Science.

[46]  R. Barbour,et al.  Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood , 2008, Neurodegenerative Diseases.

[47]  D. Allsop,et al.  Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  P. Scheltens,et al.  A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT , 2001, Stroke.

[49]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[50]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[51]  R. Panush.  Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis , 2011 .

[52]  K. Pandey,et al.  Markers of oxidative stress in erythrocytes and plasma during aging in humans , 2010, Oxidative medicine and cellular longevity.

[53]  H. Wiśniewski,et al.  Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease , 2000 .